188 related articles for article (PubMed ID: 30209238)
1. Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease.
Stefaniak JD; Parkes LM; Parry-Jones AR; Potter GM; Vail A; Jovanovic A; Smith CJ
Neurology; 2018 Oct; 91(15):e1413-e1422. PubMed ID: 30209238
[TBL] [Abstract][Full Text] [Related]
2. Determinants of white matter hyperintensity burden in patients with Fabry disease.
Rost NS; Cloonan L; Kanakis AS; Fitzpatrick KM; Azzariti DR; Clarke V; Lourenco CM; Germain DP; Politei JM; Homola GA; Sommer C; Üçeyler N; Sims KB
Neurology; 2016 May; 86(20):1880-6. PubMed ID: 27164662
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
[TBL] [Abstract][Full Text] [Related]
4. Increased resting cerebral blood flow in adult Fabry disease: MRI arterial spin labeling study.
Phyu P; Merwick A; Davagnanam I; Bolsover F; Jichi F; Wheeler-Kingshott C; Golay X; Hughes D; Cipolotti L; Murphy E; Lachmann RH; Werring DJ
Neurology; 2018 Apr; 90(16):e1379-e1385. PubMed ID: 29661900
[TBL] [Abstract][Full Text] [Related]
5. Effect of Enzyme Replacement Therapy on Basilar Artery Diameter in Male Patients With Fabry Disease.
Miwa K; Yagita Y; Sakaguchi M; Kitagawa K; Sakai N; Mochizuki H
Stroke; 2019 Apr; 50(4):1010-1012. PubMed ID: 30852964
[TBL] [Abstract][Full Text] [Related]
6. Determinants of cerebral radiological progression in Fabry disease.
Körver S; Longo MGF; Lima MR; Hollak CEM; El Sayed M; van Schaik IN; Vedolin L; Dijkgraaf MGW; Langeveld M
J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):756-763. PubMed ID: 32317398
[TBL] [Abstract][Full Text] [Related]
7. Progression of white matter hyperintensities of presumed vascular origin increases the risk of falls in older people.
Callisaya ML; Beare R; Phan T; Blizzard L; Thrift AG; Chen J; Srikanth VK
J Gerontol A Biol Sci Med Sci; 2015 Mar; 70(3):360-6. PubMed ID: 25199911
[TBL] [Abstract][Full Text] [Related]
8. Cystatin C, a potential marker for cerebral microvascular compliance, is associated with white-matter hyperintensities progression.
Lee WJ; Jung KH; Ryu YJ; Kim JM; Lee ST; Chu K; Kim M; Lee SK; Roh JK
PLoS One; 2017; 12(9):e0184999. PubMed ID: 28910415
[TBL] [Abstract][Full Text] [Related]
9. On the computational assessment of white matter hyperintensity progression: difficulties in method selection and bias field correction performance on images with significant white matter pathology.
Valdés Hernández Mdel C; González-Castro V; Ghandour DT; Wang X; Doubal F; Muñoz Maniega S; Armitage PA; Wardlaw JM
Neuroradiology; 2016 May; 58(5):475-85. PubMed ID: 26833053
[TBL] [Abstract][Full Text] [Related]
10. Development and clinical consequences of white matter lesions in Fabry disease: a systematic review.
Körver S; Vergouwe M; Hollak CEM; van Schaik IN; Langeveld M
Mol Genet Metab; 2018 Nov; 125(3):205-216. PubMed ID: 30213639
[TBL] [Abstract][Full Text] [Related]
11. Long-term progression of white matter hyperintensities in ischemic stroke.
Holmegaard L; Jensen C; Redfors P; Blomstrand C; Jern C; Jood K
Acta Neurol Scand; 2018 Dec; 138(6):548-556. PubMed ID: 30152523
[TBL] [Abstract][Full Text] [Related]
12. White matter hyperintensity progression and late-life depression outcomes.
Taylor WD; Steffens DC; MacFall JR; McQuoid DR; Payne ME; Provenzale JM; Krishnan KR
Arch Gen Psychiatry; 2003 Nov; 60(11):1090-6. PubMed ID: 14609884
[TBL] [Abstract][Full Text] [Related]
13. Microstructural and metabolic changes in the longitudinal progression of white matter hyperintensities.
Jiaerken Y; Luo X; Yu X; Huang P; Xu X; Zhang M;
J Cereb Blood Flow Metab; 2019 Aug; 39(8):1613-1622. PubMed ID: 29519198
[TBL] [Abstract][Full Text] [Related]
14. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
[TBL] [Abstract][Full Text] [Related]
15. UBO Detector - A cluster-based, fully automated pipeline for extracting white matter hyperintensities.
Jiang J; Liu T; Zhu W; Koncz R; Liu H; Lee T; Sachdev PS; Wen W
Neuroimage; 2018 Jul; 174():539-549. PubMed ID: 29578029
[TBL] [Abstract][Full Text] [Related]
16. Higher blood-brain barrier permeability is associated with higher white matter hyperintensities burden.
Li Y; Li M; Zhang X; Shi Q; Yang S; Fan H; Qin W; Yang L; Yuan J; Jiang T; Hu W
J Neurol; 2017 Jul; 264(7):1474-1481. PubMed ID: 28653212
[TBL] [Abstract][Full Text] [Related]
17. Disease Progression Modeling to Evaluate the Effects of Enzyme Replacement Therapy on Kidney Function in Adult Patients with the Classic Phenotype of Fabry Disease.
Nowak A; Koch G; Huynh-Do U; Siegenthaler M; Marti HP; Pfister M
Kidney Blood Press Res; 2017; 42(1):1-15. PubMed ID: 28253518
[TBL] [Abstract][Full Text] [Related]
18. White matter hyperintensity reduction and outcomes after minor stroke.
Wardlaw JM; Chappell FM; Valdés Hernández MDC; Makin SDJ; Staals J; Shuler K; Thrippleton MJ; Armitage PA; Muñoz-Maniega S; Heye AK; Sakka E; Dennis MS
Neurology; 2017 Sep; 89(10):1003-1010. PubMed ID: 28794252
[TBL] [Abstract][Full Text] [Related]
19. Retinal image analytics detects white matter hyperintensities in healthy adults.
Lau AY; Mok V; Lee J; Fan Y; Zeng J; Lam B; Wong A; Kwok C; Lai M; Zee B
Ann Clin Transl Neurol; 2019 Jan; 6(1):98-105. PubMed ID: 30656187
[TBL] [Abstract][Full Text] [Related]
20. Severity of White Matter Hyperintensities and Effects on All-Cause Mortality in the Mayo Clinic Florida Familial Cerebrovascular Diseases Registry.
Hasan TF; Barrett KM; Brott TG; Badi MK; Lesser ER; Hodge DO; Meschia JF
Mayo Clin Proc; 2019 Mar; 94(3):408-416. PubMed ID: 30832790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
